The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
35
IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
Unnamed facility
Little Rock, Arkansas, United States
Unnamed facility
West Hollywood, California, United States
Unnamed facility
Miami, Florida, United States
Unnamed facility
Bethesda, Maryland, United States
Phase I: toxicity defined in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 12/12/03
Time frame: 6 months
Phase II efficacy using EMBT criteria.
Time frame: 6 months
Safety
Time frame: 6 months
Pharmacokinetics of ZIO-101
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
New York, New York, United States
Unnamed facility
Cleveland, Ohio, United States
Unnamed facility
Edmonton, Alberta, Canada
Unnamed facility
Toronto, Ontario, Canada